What are the long-term health risks of PCOS?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
PCOS carries a higher long-term risk of type 2 diabetes, gestational diabetes, endometrial hyperplasia and endometrial cancer, obstructive sleep apnoea, depression and cardiovascular disease. The 2023 international guideline states the diabetes risk applies regardless of age and body weight. Most of these risks are monitorable, and several are modifiable.
Get urgent care if: you have PCOS and develop any of the following bleeding patterns:
- Bleeding that soaks through a pad or tampon every hour for several hours
- Bleeding that has continued for more than a week without stopping
- Any vaginal bleeding after menopause
- Bleeding with dizziness, breathlessness or fainting
PCOS is a lifelong condition, and the reason clinicians take it seriously beyond periods and hair is the long-term risk profile. The 2023 International Evidence-based Guideline lists increased risk of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes "regardless of age and BMI", increased cardiovascular disease risk, markedly higher risk of endometrial hyperplasia and endometrial cancer, higher rates of obstructive sleep apnoea independent of body weight, and a high prevalence of moderate to severe depressive symptoms.
Metabolic and pregnancy risks
Glucose problems appear earlier and progress faster in PCOS. The guideline recommends the 75 g oral glucose tolerance test as the most accurate assessment of glycaemic status regardless of BMI, reassessed every one to three years based on individual risk factors. In pregnancy, the RCOG guideline on long-term consequences of PCOS states that the prevalence of gestational diabetes is twice as high among women with PCOS compared with controls, which is why screening in pregnancy is brought forward.
Endometrial risk and what reduces it
Long gaps between periods leave the endometrium exposed to oestrogen without the opposing effect of progesterone, and that is the mechanism behind hyperplasia. The RCOG guideline cites a 2.89-fold increased risk of endometrial cancer in women with PCOS (95% CI 1.52 to 5.48), with no association found for breast or ovarian cancer. Routine screening is not recommended because the absolute risk remains low. What reduces it is regular endometrial shedding or continuous progestin: RCOG considers it good practice to induce a withdrawal bleed at least every three to four months.
Sleep, mood and cardiovascular risk
Obstructive sleep apnoea is significantly more common in PCOS independent of BMI, and the guideline asks clinicians to screen when snoring occurs with waking unrefreshed, daytime sleepiness or fatigue. Depression screening is recommended for all adults and adolescents with PCOS using regionally validated tools, and eating disorders should be considered regardless of weight. Cardiovascular risk is elevated, though the guideline is careful to note that absolute cardiovascular risk in premenopausal women remains low.
| Risk | What is monitored | Interval |
|---|---|---|
| Type 2 diabetes | 75 g oral glucose tolerance test | Every 1 to 3 years |
| Cardiovascular | Lipid profile at diagnosis, blood pressure | Blood pressure annually |
| Endometrial | Bleeding pattern, ultrasound if abnormal | Bleed at least every 3 to 4 months |
| Sleep apnoea | Symptom screening, sleep study if positive | When symptoms present |
| Mood | Validated depression screening | At diagnosis and periodically |
Ask for these to be written into a schedule rather than raised opportunistically. A woman with PCOS who has an OGTT every two years, a lipid panel, an annual blood pressure and a defined bleeding plan is being managed properly, whatever else is happening with her symptoms.
The clinical detail
Guideline recommendation numbers: glycaemic status via 75 g OGTT regardless of BMI (1.9.9), reassessed every one to three years (1.9.3); lipid profile at diagnosis in all women regardless of age and BMI (1.8.3); blood pressure annually and when planning pregnancy or fertility treatment (1.8.4); increased cardiovascular disease risk acknowledged alongside low absolute premenopausal risk (1.8.1); higher OSA prevalence independent of BMI with symptom-based screening (1.10.1, 1.10.2); depression screening in all adults and adolescents (2.2.1); disordered eating considered regardless of weight (2.5.1).
RCOG Green-top Guideline 33 figures: endometrial cancer risk 2.89-fold increased (95% CI 1.52 to 5.48), no association with breast or ovarian cancer, gestational diabetes prevalence twice that of controls. An endometrial thickness below 7 mm on transvaginal ultrasound is reassuring; a thickened endometrium or polyp prompts consideration of biopsy or hysteroscopy.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- International Evidence-based Guideline for the Assessment and Management of PCOS, 2023 summary. Monash University Centre for Health Research and Implementation
- Long-term Consequences of Polycystic Ovary Syndrome, Green-top Guideline No. 33. Royal College of Obstetricians and Gynaecologists
- Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism. PMID 37580314
- Recommendations from the 2023 International Evidence-based Guideline for PCOS. Human Reproduction. PMID 37580037
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.